---
schema_version: "secwatch.filing_event.v1"
accession: "0001821586-25-000009"
form_type: "8-K"
ticker: "MLTX"
cik: "0001821586"
company_name: "MoonLake Immunotherapeutics"
filed_at: "2025-05-12T23:59:59+00:00"
generated_at: "2026-05-22T00:16:52.456394+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# MoonLake reports Q1 2025 cash of $480.1M, secures up to $500M debt facility; Phase 3 HS enrollment complete

## Summary
- Cash, cash equivalents and short-term marketable debt securities of $480.1M as of March 31, 2025.
- Up to $500M non-dilutive debt facility with Hercules Capital; $75M drawn at close, extends cash runway into 2028.
- Phase 3 VELA program in hidradenitis suppurativa fully enrolled; top-line results expected around September 2025.
- R&D expenses $36.5M (similar to prior quarter); G&A expenses $11.0M (up from $9.2M).
- Interim readout of Phase 2 LEDA trial in palmoplantar pustulosis presented; primary endpoint readout expected 2H 2025.

## SEC filing metadata
- accession: 0001821586-25-000009
- form_type: 8-K
- ticker: MLTX
- cik: 0001821586
- company_name: MoonLake Immunotherapeutics
- filed_at: 2025-05-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1821586/000182158625000009/0001821586-25-000009-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1821586/000182158625000009/mnlk-20250512.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001821586-25-000009
- JSON: https://secwatch.observer/filing/0001821586-25-000009.json
- Plain text: https://secwatch.observer/filing/0001821586-25-000009.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.